The U.S. Food and Drug Administration has officially approved the nation’s first messenger RNA (mRNA) flu vaccine, offering a new line of defense for older adults ahead of the 2026-2027 respiratory virus season.
Manufactured by Moderna, the new vaccine—named mFLUSIVA—received standard approval in August for adults ages 50 to 64, alongside accelerated approval for those 65 and older. The rollout marks a significant milestone in immunology, adapting the groundbreaking mRNA technology popularized during the COVID-19 pandemic to combat seasonal influenza [cite: 1.2.1].
How the mRNA Vaccine Differs
Unlike traditional flu shots, which rely on inactivated viruses grown in eggs or cell cultures, mFLUSIVA does not contain any whole flu virus.
Instead, the vaccine uses lipid particles to deliver a small sequence of genetic code (mRNA) into the body’s cells. This code provides temporary instructions, prompting the cells to produce a harmless flu protein known as hemagglutinin [cite: 1.2.2]. The immune system recognizes this protein and builds antibodies against it, preparing the body to rapidly fight off a future infection [cite: 1.2.2]. Once the instructions are delivered, the mRNA breaks down naturally without entering the cell’s nucleus or altering a patient’s DNA [cite: 1.2.2].
A major advantage of this mRNA approach is its manufacturing speed. Traditional flu vaccines often require strain selection as early as February [cite: 1.1.4]. Because mRNA sequences are easier to copy in a lab, manufacturers can wait until May to finalize the formula, allowing the vaccine to more accurately match the specific flu strains currently circulating in the wild.
Efficacy and Availability
Early data suggests the new approach is highly effective. In a clinical trial involving over 40,000 participants, Moderna reported that mFLUSIVA was approximately 27% more effective than standard flu shots at preventing flu-like illnesses during the 2024-2025 testing season.
However, patients should be prepared for slightly more frequent side effects. Roughly 75% of mFLUSIVA recipients reported at least one mild, short-term reaction—such as injection site tenderness, fatigue, headache, chills, or muscle aches—compared to 47% of those receiving standard-dose vaccines [cite: 1.2.2]. Experts note these reactions are generally temporary and dissipate within two days [cite: 1.2.2].
Additionally, the 2026-2027 formula contains no egg protein, antibiotics, or preservatives [cite: 1.2.2].
Moderna has stated that mFLUSIVA is currently available at more than 13,000 locations nationwide [cite: 1.1.4]. However, initial supplies may be limited at major pharmacy chains like CVS and Walgreens, as many pre-ordered their seasonal stock earlier in the year [cite: 1.1.4]. Health experts emphasize that while the mRNA option is promising, older adults should not delay getting vaccinated if their preferred shot is temporarily out of stock; getting any age-appropriate flu vaccine remains a safe and reliable way to reduce your flu risk.


